Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nov 13 2019 Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results Nov 07 2019 Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results Nov 06 2019 Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting Sep 23 2019 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 09 2019 Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors Sep 04 2019 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference Aug 13 2019 Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results Aug 07 2019 Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results Jul 22 2019 Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients May 14 2019 Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results May 08 2019 Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results Apr 01 2019 Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019 Mar 27 2019 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Mar 25 2019 Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor Mar 20 2019 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results Mar 13 2019 Cyclacel to Participate in 31st Annual ROTH Conference March 18-19 Mar 05 2019 Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019 Feb 05 2019 Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference Jan 07 2019 Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 Dec 27 2018 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Nov 12 2018 Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results Nov 06 2018 Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results Oct 23 2018 Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference Oct 04 2018 Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies Sep 26 2018 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nov 13 2019 Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results Nov 07 2019 Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results Nov 06 2019 Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting Sep 23 2019 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 09 2019 Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors Sep 04 2019 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference Aug 13 2019 Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results Aug 07 2019 Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results Jul 22 2019 Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients May 14 2019 Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results May 08 2019 Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results Apr 01 2019 Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019 Mar 27 2019 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Mar 25 2019 Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor Mar 20 2019 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results Mar 13 2019 Cyclacel to Participate in 31st Annual ROTH Conference March 18-19 Mar 05 2019 Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019 Feb 05 2019 Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference Jan 07 2019 Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 Dec 27 2018 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Nov 12 2018 Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results Nov 06 2018 Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results Oct 23 2018 Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference Oct 04 2018 Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies Sep 26 2018 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
Nov 06 2019 Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
Sep 09 2019 Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
Sep 04 2019 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Jul 22 2019 Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients
Apr 01 2019 Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019
Mar 25 2019 Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor
Mar 05 2019 Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019
Jan 07 2019 Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019
Oct 04 2018 Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies
